sYNoPsis The effect upon tryptophan metabolism of the use of combined oestrogen-progestagen oral contraceptives containing a low (0.05 mg) dose of oestrogen, or of the continuous administration of megestrol acetate, has been studied by determining the excretion of tryptophan metabolites in urine collected after a 2 g oral dose of the amino acid.
There have been several reports of disturbed tryptophan metabolism in women using oral contraceptives, the abnormality being characterized by an elevated excretion of xanthurenic acid and other metabolites of the tryptophan-nicotinic acid pathway ( Fig. 1 ) in urine collected after an oral dose of the amino acid (Rose, 1965 (Rose, , 1966 Price, Thornton, and Mueller, 1967; Luhby, Davis, Murphy, Gordon, Brin, and Spiegel, 1970) . These changes are similar to the altered excretion of tryptophan metabolites which occurs in vitamin B6 deficiency, they are reversed by treatment with large doses of pyridoxine, and they are also present in patients treated with oestrogens alone (Brown, Rose, Price, and Wolf, 1969) .
Received for publication 13 September 1971. 252 The clinical significance of the disordered tryptophan metabolism produced by oestrogens remains to be established, but, as will be discussed later, it may be related to two recognized complications of the use of oral contraceptives-mental depression and impaired glucose tolerance.
The women studied in previous investigations were using a combined oestrogen-progestagen type of oral contraceptive, and the majority were receiving a high dose of oestrogen (0'075 to 0-1 mg). Rose (1966) did report abnormal tryptophan metabolism by five women taking a preparation containing only 0-05 mg ethinyl oestradiol, but the 5 g dose of L-tryptophan which he used in his original study is equal to approximately five times the normal daily dietary intake of this amino acid, and is therefore a grossly unphysiological load. The advantages of using a 2 g tryptophan load have been discussed by Price, Brown, and Yess (1965) . Since the recommendations of the Committee on Safety of Drugs (Scowen, 1969 ) the dose of ethinyl oestradiol or its 3-methyl ether, mestranol, in the combined oestrogen-progestagen oral contraceptives now in common use in the United Kingdom has been limited to 0 05 mg. Clinical and biochemical investigation of continuous low-dosage progestagen preparations given alone indicate that these steroids provide an alternative form of oral contraception which is moderately efficient and is not associated with significant metabolic abnormalities (Mears, Vessey, Andolsek, and Oken, 1969; Larsson-Cohn, Tengstrom, and Wide, 1969) .
Therefore, in the present investigation we have reassessed the effects on tryptophan metabolism of combined oral contraceptives containing a low dose of oestrogen, and, as the effects of continuous lowdosage progestagen administration on tryptophan metabolism have not been reported, we have studied these in women taking megestrol acetate 0 5 mg daily.
Subjects and Methods
Ten women were studied before they started to take an oral contraceptive, and the tests were then repeated after the administration of an oestrogenprogestagen preparation for 21 days, and again after three months. The preparations used and the number taking each one are given in Table I . A further 10 women were investigated when they had been taking a combined type of oral contraceptive for six to 18 months (Table II) . Four subjects taking oral contraceptives were studied before and after the administration of pyridoxine hydrochloride, 20 mg daily, for one month.
Tryptophan metabolism by four other subjects (Table II, nos. 3, 4, 8, 9) was assessed when they had been using an oral contraceptive for several months, and then at intervals after they had discontinued its use.
Five women were investigated when they had been taking megestrol acetate, 0-5 mg daily, for three to 23 months (Table V) (Walsh, 1965) , and kynurenine, 3-hydroxykynurenine, and 3-hydroxyanthranilic acid by the ion-exchange chromatography method of Heeley (1965) . Statistical examination of the results was by Student's t test, differences giving P = 005 being regarded as significant.
Results
After 21 days' treatment with a combined type of oral contraceptive there was a significant increase in the urinary xanthurenic acid excretion (p < 0 01; Table III ), only one of the 10 subjects not having an elevated excretion of this metabolite. However, the excretions of kynurenine, 3-hydroxykynurenine, and 3-hydroxyanthranilic acid were unchanged (Table  III) . By three months the xanthurenic acid excretions were considerably higher than they had been at 21 days, and there were also increases in themeanvalues for the excretion of the other three metabolites, although, owing to the considerable degree of variance within the groups, these changes were not statistically significant.
The tryptophan metabolite excretions by the 10 patients who had been taking an oestrogen-containing preparation for six months or more are given in Table II . They all excreted grossly elevated levels of xanthurenic acid, all but one (no. 5) excreted markedly increased quantities of kynurenine and 3-hydroxykynurenine, and in six there was a raised excretion of 3-hydroxyanthranilic acid. Comparison of the excretion of metabolites after three months treatment with the urinary levels of the women who had been taking an oral contraceptive for six months or longer (Table III) showed that prolonged administration ofa preparation containing 0 05 mg of oestrogen results in an accentuation of the metabolic disturbance, significant further increases occurring in the excretions of xanthurenic acid (p < 0 01), kynurenine, and 3-hydroxykynurenine (p < 0-05). The rate of return of tryptophan metabolism to normal after discontinuing oral contraceptives is illustrated in Fig. 2 , and it is apparent that there is an association between the severity of the initial abnormal excretion of metabolites and the time required for the levels to reach pretreatment values. The levels of tryptophan metabolites in the urine of five women taking megestrol acetate are given in Table V . Subject no. 14 had been using an oestrogencontaining oral contraceptive until three months before the metabolic studies, and it seems likely that the elevated excretions of kynurenine, 3-hydroxykynurenine, and 3-hydroxyanthranilic acid reflect a residual oestrogen effect. The xanthurenic acid (1967) in their study of women who had been receiving Enavid-E for several cycles. There is a higher excretion of xanwas normal. Subject no. 15 appeared to thurenic acid by the Enavid-E-treated group comslightly increased quantity of 3-hydroxy-pared with the subjects who had received the lower ic acid, but the levels of the other meta-dose of oestrogen for six months or more, but the re normal. levels of kynurenine and 3-hydroxykynurenine are similar. The group of women treated with 0 05 mg n oestrogen for only three months excreted lower levels of these metabolites than the Enavid-E-treated nt study has shown that a reduction of the women. These results suggest that the severity of the component of the combined types of oral disturbance of tryptophan metabolism is influenced tive to 005 mg does not eliminate the by both the dose of oestrogen in the oral contrametabolism of a 2 g tryptophan load ceptive and by the duration of its administration. s previously been noted with Enavid-E, a Recently, Rose and McGinty (1970) have reviewed on containing 0 1 mg mestranol and 2-5 mg the possible mechanisms by which oestrogens may odrel (Price et al, 1967 ). An elevated influence metabolism along the tryptophan-nicotinic excretion of xanthurenic acid becomes acid pathway. It is suggested that these steroids both after only 21 days of treatment with a low-stimulate the activity of tryptophan oxygenase, the ;rogen oral contraceptive, although at this first and rate-limiting enzyme, and also inhibit the supernatant pyridoxal phosphate-dependent enzymes of the pathway, but not the mitochondrial aminotransferase which yields xanthurenic acid (Fig.  1 ). There is evidence from animal studies in support of both these possibilities (Braidman and Rose, 1971; Mason, Ford, and Wu, 1969) .
Regardless of the precise biochemical mechanisms involved in the production of the metabolic disturbance, its correction by treatment the aetiology of depression (Curzon, 1969 Fig. 1) , and Rose (1971) has recently reviewed the biochemical evidence in support of both this hypo-thesis, and the possibility that increased turnover of the tryptophan-nicotinic acid ribonucleotide pathway, due to oestrogen action, results in a lack of substrate for 5-hydroxytryptamine biosynthesis. Abnormal tryptophan metabolism occurs in rheumatoid arthritis (McMillan, 1960; Bett, 1966) , and rheumatic symptoms may develop during the use of oral contraceptives (Bole, Friedlander, and Smith, 1969; Spiera and Plotz, 1969) . However, the precise mechanism for the elevated excretion of tryptophan metabolites in rheumatoid arthritis remains to be established, and so for the present the clinical significance of any association between abnormal tryptophan metabolism and rheumatic complaints in oral contraceptive-treated women is uncertain. Doar (1966, 1970) observed impaired oral glucose tolerance in over 75 % of women using a combined type of oral contraceptive, and in 13 % there was chemical diabetes mellitus. They drew attention to the elevated plasma cortisol levels which occur during oestrogen administration, andpostulated that the changes in glucose tolerance in women receiving oral contraceptives result from exposure of the liver to high glucocorticoid concentrations. In a further paper, Doar and Wynn (1970) pointed out the similarity between the changes in glucose tolerance and pyruvate metabolism observed in nonobese subjects taking oestrogen-containing oral contraceptives and those seen in non-obese patients treated with glucocorticoids and obese non-diabetic patients not receiving steroids, and they suggested that the metabolic abnormality in all three situations results from excessive glucocorticoid activity. The high levels of corticosteroid-inducible enzymes in the livers of oestrogen-treated rats, and the changes in tryptophan metabolism in oestrogen-treated human subjects, women using oestrogen-containing oral contraceptives, and subjects treated with hydrocortisone (Rose and McGinty, 1968) provide strong indirect support for this hypothesis.
Impaired glucose tolerance may also be directly related to the abnormal tryptophan metabolism by women taking oral contraceptives. The elevated urinary levels of xanthurenic acid which were observed in the present study are presumably accompanied by high plasma and liver concentrations of this metabolite, and experimental work by Kotake et al (1968) has shown that xanthurenic acid is capable of forming a complex with insulin which reduces the effect of this hormone on the blood glucose level by about 50 %. The clinical significance of this interesting observation remains to be established.
Impaired glucose tolerance may persist for six weeks or more after withdrawal of an oral contra-257 ceptive and so it is especially noteworthy that abnormal tryptophan metabolism has been demonstrated eight to 15 weeks after discontinuing the administration of these preparations.
Studies of individual steroids indicate that the abnormalities of both carbohydrate and tryptophan metabolism in women using the combined types of oral contraceptives are produced by the oestrogen component alone (Di Paola, Robin, and Nicholson, 1970; Rose, 1966) . Consistent with this is the present observation that the continuous administration of the progestagen megestrol acetate in low dosage for contraceptive purposes does not produce any significant change in tryptophan metabolism, and also that in a recent study of this steroid it has been shown to have no effect upon glucose tolerance (Adams and Wynn, 1971 ). In addition, we have found that another 17a-hydroxyprogesterone derivative, medroxyprogesterone acetate, does not alter tryptophan metabolism (unpublished data).
